A Planned Parenthood official falsely asserted that the abortion pill is “safer than many over-the-counter medications — including Tylenol.”
Never mind that that claim has been repeatedly refuted.
a fundraising email responding to legislation introduced by pro-life Senator Josh Hawley and his bill to take the dangerous abortion drug off the market, Sarah Taylor-Nanista, executive director of Planned Parenthood Votes Colorado, defended the drug’s safety.
“This bill is built on false claims that the medication is ‘inherently dangerous,’ despite decades of scientific evidence showing that mifepristone is safer than many over-the-counter medications — including Tylenol,” Taylor-Nanista wrote.
SUPPORT LIFENEWS! If you want to help fight abortion, please donate to LifeNews.com!
Hawley’s Safeguarding Women from Chemical Abortion Act, introduced Wednesday, seeks to revoke the Food and Drug Administration’s approval of mifepristone for abortion use, allow women harmed by the drug to sue manufacturers and classify labeling or distribution violations related to abortion as breaches of federal food and drug law.
Hawley said the measure addresses harms to women: “No amount of profit justifies what has happened to these women. Congress must ban the chemical abortion drug and empower women to sue its manufacturers.”
The bill follows a report from the Ethics and Public Policy Center analyzing 865,727 mifepristone abortions from 2017 to 2023, which found that 10.93% of women experienced serious adverse events such as sepsis, infection or hemorrhaging within 45 days.
Researchers have directly rebutted the “safer than Tylenol” claim.
A peer-reviewed article published in the journal BioTech by Cameron Louttit, Ph.D., director of life sciences at the Charlotte Lozier Institute, concluded that no controlled, scientifically appropriate study supports direct comparisons between mifepristone and acetaminophen (Tylenol), given their different uses, administration methods and user risk profiles.
Louttit wrote: “Put simply, it is not possible to draw any conclusion from the comparison of drugs with different uses, administered in different manners, and used by individuals with different risk factors… Not only have the comparisons between mifepristone and other drugs failed in their duty to adequately assess this impossibility, but they have also demonstrated a complete disregard for the need to communicate comprehensive and truthful safety information to patients, policymakers, jurists, and the public.”
Louttit added: “The simplistic slogan that ‘mifepristone is safer than Tylenol,’ though easily disseminated, defies both an intuitive understanding of how we evaluate drug safety and our norms and regulations for doing so… if such an assertion was attributable to the manufacturer, it would precipitate a reprimand by the FDA given the lack of specific, controlled, and head-to-head evidence rightly required for its support.
